Compare · ABBV vs DAWN
ABBV vs DAWN
Side-by-side comparison of AbbVie Inc. (ABBV) and Day One Biopharmaceuticals Inc. (DAWN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and DAWN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $394.12B, about 454.3x DAWN ($867.6M).
- Over the past year, ABBV is up 18.0% and DAWN is up 203.4% - DAWN leads by 185.4 points.
- ABBV has hit the wire 10 times in the past 4 weeks while DAWN has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 13 for DAWN).
- Company
- AbbVie Inc.
- Day One Biopharmaceuticals Inc.
- Price
- $223.01-1.80%
- $21.52+0.14%
- Market cap
- $394.12B
- $867.6M
- 1M return
- +10.05%
- +0.70%
- 1Y return
- +17.97%
- +203.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 13
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest DAWN
- Amendment: SEC Form SCHEDULE 13G/A filed by Day One Biopharmaceuticals Inc.
- SEC Form 15-12G filed by Day One Biopharmaceuticals Inc.
- SEC Form 4 filed by Large owner Ai Day1 Llc
- CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- COO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Gen Counsel & Secretary Dubow Adam returned 72,694 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Holles Natalie C. returned 57,310 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Director Ramasastry Saira returned 40,485 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Josey John A. returned 72,292 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)